Drug intelligence / Profile preview

cisplatin + gedatolisib

Development stage: Unknown
Lead developer: Celcuity
Modality: Small Molecules
Administration: Intravenous

Overview

Cisplatin + gedatolisib is a combination therapy consisting of cisplatin, a platinum-based chemotherapeutic agent, and gedatolisib (PF-05212384), a dual PI3K/mTOR inhibitor. This combination has been studied in clinical trials for the treatment of triple-negative breast cancer (TNBC) and other advanced solid tumors. The rationale for this combination is that inhibition of PI3K-mediated signaling by gedatolisib may help overcome resistance to chemotherapy agents like cisplatin.

Targets

mTOR (Mammalian target of rapamycin kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)DNA

Beyond the preview

Go deeper on cisplatin + gedatolisib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + gedatolisib.

Explore the full profile